Global expansion of Idorsia’s QUVIVIQ continues with EMS partnership for Latin America

Core Viewpoint - Idorsia Ltd has entered into an exclusive license and supply agreement with EMS S.A. to commercialize QUVIVIQ™ (daridorexant) in Latin America, marking a significant step in the company's global expansion strategy [2][3]. Company Overview - Idorsia is focused on developing transformative medicines and aims to challenge existing medical paradigms. The company is headquartered in Allschwil, Switzerland, and is listed on the SIX Swiss Exchange [15][16]. - EMS S.A. is Brazil's largest privately-owned pharmaceutical company, with over 60 years of history and a strong market presence in various pharmaceutical segments [13][14]. Product Information - QUVIVIQ is an innovative treatment for insomnia that selectively blocks orexin receptors, promoting restorative sleep without broadly suppressing brain activity. It is designed to improve both sleep quality and daytime functioning [5][6]. - Clinical trials have shown that daridorexant significantly improves sleep onset, maintenance, and total sleep time, with a notable enhancement in daytime functioning at a 50 mg dose compared to placebo [6]. Market Potential - Insomnia affects millions in Latin America, with current treatments often leading to next-day drowsiness and dependence, indicating a strong unmet need for safer alternatives [4][11]. - The partnership with EMS is expected to enhance the availability of QUVIVIQ in Latin America, reinforcing Idorsia's commitment to making the product a global brand [7][10]. Financial Terms - Idorsia is set to receive a total milestone compensation of USD 20 million for the execution of the agreement, along with supply prices and double-digit royalties on net sales in Brazil and Mexico [10].